An AI-designed vaccine built to cover a whole branch of coronaviruses has cleared its first human safety trial, giving pandemic planners something rare: a small but real reason to look ahead rather than simply sprint after the next variant. The experimental shot, called pEVAC-PS, was developed by scientists connected to the University of Cambridge and biotechnology company DIOSynVax. Early Phase I results published in the Journal of Infection found it was safe and well tolerated in healthy adult volunteers.

What is pEVAC-PS designed to do?

pEVAC-PS is a pan-Sarbecovirus vaccine, which means it is intended to train the immune system against a wider family of viruses rather than one single strain. That family includes SARS-CoV-1, which caused the 2003 SARS outbreak, SARS-CoV-2, which causes COVID-19, and related coronaviruses circulating in animals.

That last category is the uncomfortable part. Some animal coronaviruses have the potential to spill over into humans, and history has not been subtle about how disruptive that can be.

Traditional vaccines often focus on a specific virus or variant. This candidate takes a different route: it uses computational design and machine learning to identify viral features shared across related viruses. The aim is to target parts of the virus that are harder for it to change without compromising itself.

How did the first human trial work?

The Phase I trial enrolled healthy adults aged 18 to 50 who had already received two or three doses of existing COVID-19 vaccines. Between December 2021 and September 2023, 39 volunteers received pEVAC-PS.

Participants were given two doses, 28 days apart. The study used escalating dose groups, ranging from 0.2 milligrams to 1.2 milligrams, to assess safety across four dose levels.

The trial was open-label, meaning participants and investigators knew what was being administered. Its main goal was not to prove the vaccine prevents COVID-19, SARS, or any future infection. Instead, researchers were primarily measuring:

  • Safety
  • Reactogenicity, or short-term post-vaccination symptoms
  • Early immune responses after the second dose

Investigators reported no significant safety concerns across the dose groups.

What did researchers find about immune response?

The study found that pEVAC-PS triggered measurable immune responses to conserved sarbecovirus epitopes encoded by the vaccine. In plain language, the shot appeared to direct the immune system toward shared pieces of related coronaviruses, which is the central idea behind the whole project.

The results were not framed as a victory lap. The researchers described immunogenicity as modest, and the study was small. Participants also had pre-existing immunity from prior COVID-19 vaccination, and recruitment overlapped with Omicron waves, which likely created uneven exposure histories among volunteers.

So no, this is not the moment where someone should declare the pandemic problem solved. Science remains inconveniently unwilling to follow press-release pacing.

Still, the findings support the feasibility of the design strategy: using selected conserved viral targets to build a broader vaccine candidate before the next related virus becomes a public health emergency.

Where does artificial intelligence fit in?

The artificial intelligence behind pEVAC-PS is not the chatbot version of AI being asked to summarize meeting notes. It is a computational biology approach used to compare viral genetic and structural data, then select immune targets shared across related viruses.

DIOSynVax describes its platform as one that analyses viral structure and evolution, using computational modelling to assemble epitope-rich regions into synthetic vaccine antigen designs.

Professor Jonathan Heeney, linked to the University of Cambridge’s viral zoonotics work and DIOSynVax, has described the goal as “one vaccine that will get them all.” The phrase is blunt, but the underlying concept is serious: develop vaccines that protect across a viral family instead of updating shots after every major evolutionary swerve.

That would mark a shift from the reactive model that dominated COVID-19 vaccine updates. In that model, a pathogen spreads, researchers identify the threat, manufacturers adapt, and the public waits. It worked at remarkable speed in 2020. It was also, to put it gently, not ideal as a global operating system.

How is the vaccine delivered?

pEVAC-PS is a DNA vaccine delivered into the skin using the PharmaJet Tropis needle-free intradermal system. Rather than a standard syringe, the device uses a high-pressure microfluid jet.

Researchers say DNA vaccine delivery may offer practical advantages, including improved thermostability and easier use in lower-resource settings. Those details matter because vaccination campaigns are not only biology problems. They are logistics problems involving refrigeration, trained staff, sharps disposal, transport, public trust, and all the other unglamorous machinery that determines whether a dose reaches an arm.

Why are scientists pursuing broader coronavirus vaccines?

The scientific groundwork for pEVAC-PS has been developing for years. Earlier preclinical work by Cambridge researchers used a computationally designed antigen based on the receptor-binding domain of sarbecovirus spike proteins. In animal models, that design produced broad antibody responses against SARS-CoV-1, SARS-CoV-2, WIV16, and RaTG13.

That research pointed toward a larger pandemic-preparedness strategy: target shared features across related coronaviruses before a zoonotic spillover becomes a global crisis.

Public health experts have warned for years that coronaviruses remain a recurring threat because related viruses continue to circulate in animal reservoirs. These viruses can mutate or recombine, creating opportunities for future spillovers. COVID-19 proved vaccines could be developed unusually fast. It also showed the limits of constantly chasing new variants after they have already arrived.

That is why pEVAC-PS is being watched as part of a broader race to develop universal coronavirus vaccines and other platforms designed for future outbreaks.

What happens next?

The next major step is expected to be a larger Phase II study involving more than 200 people. That trial should provide a clearer look at immune responses across a broader population, including how durable and wide-ranging those responses may be.

For now, pEVAC-PS remains experimental. It has not been shown to prevent COVID-19, SARS, or infection from future animal coronaviruses. It still faces larger trials, regulatory review, and manufacturing assessment before it could be considered for public use.

But the first human trial is an important early signal. If later studies support the approach, AI-designed vaccine technology could become a useful tool for preparing before the next pandemic begins, rather than once again trying to build the plane after takeoff. Apparently, planning ahead is still legal.